Cutler Investment Counsel’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$626K Sell
2,488
-200
-7% -$43K 0.06% 102
2026
Q1
$585K Sell
2,688
-491
-15% -$109K 0.06% 100
2025
Q4
$726K Sell
3,179
-352
-10% -$80.2K 0.08% 93
2025
Q3
$818K Buy
3,531
+207
+6% +$42.2K 0.09% 88
2025
Q2
$617K Hold
3,324
0.07% 94
2025
Q1
$696K Buy
3,324
+18
+0.5% +$3.5K 0.08% 85
2024
Q4
$587K Sell
3,306
-150
-4% -$27.6K 0.07% 91
2024
Q3
$682K Buy
3,456
+31
+0.9% +$5.79K 0.09% 83
2024
Q2
$587K Buy
3,425
+13
+0.4% +$2.15K 0.08% 85
2024
Q1
$621K Sell
3,412
-667
-16% -$115K 0.08% 85
2023
Q4
$632K Buy
4,079
+216
+6% +$31.5K 0.09% 90
2023
Q3
$576K Buy
3,863
+189
+5% +$27.7K 0.09% 88
2023
Q2
$495K Buy
3,674
+1,473
+67% +$216K 0.07% 95
2023
Q1
$351K Hold
2,201
0.05% 107
2022
Q4
$356K Hold
2,201
0.05% 106
2022
Q3
$295K Buy
2,201
+17
+0.8% +$2.44K 0.05% 105
2022
Q2
$335K Hold
2,184
0.05% 106
2022
Q1
$354K Buy
2,184
+650
+42% +$94.4K 0.05% 109
2021
Q4
$208K Buy
+1,534
New +$181K 0.03% 94

Other funds holding ABBV

Cutler Investment Counsel's ABBV Position: Q2 2026 in Review

Cutler Investment Counsel reduced its AbbVie (ABBV) stake by 7.4% in Q2 2026, selling an estimated $43K and leaving 2,488 shares worth $626K. The position accounts for 0.06% of the portfolio, ranked #102.

Cutler Investment Counsel first reported a position in ABBV in Q4 2021 and has held it in 19 quarters since. The position peaked at $818K in Q3 2025. 2,121 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Cutler Investment Counsel held 2,488 shares of AbbVie worth $626K as of Q2 2026.
  • Cutler Investment Counsel sold 200 AbbVie shares in Q2 2026, an estimated $43K.
  • AbbVie made up 0.06% of Cutler Investment Counsel's portfolio in Q2 2026, its #102 holding.
  • Cutler Investment Counsel first reported a position in AbbVie in Q4 2021 and has held it in 19 quarters since.
  • Cutler Investment Counsel's AbbVie position peaked at $818K in Q3 2025.
  • 2,121 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Cutler Investment Counsel's 13F filing for Q2 2026, filed 14 Jul 2026.